Florbenazine F 18
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Florbenazine F 18
- Molecular weight
- 364.49
- Structure (SMILES)
- COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21
- (18F)-FP-(+)-DTBZ
- (18F)AV 133
- (18F)AV-133
- (2R,3R,11BR)-9-(3-((SUP 18)F)FLUOROPROPOXY)-10-METHOXY-3-(2-METHYLPROPYL)-1,3,4,6,7,11B- HEXAHYDRO-2H-BENZO(A)QUINOLIZIN-2-OL
- 18f av 133
- 18f dtbz
- 18f fp dtbz
- 18F- DTBZ
- 18F-AV-133
- 18f-dtbz
- 18F-DTBZ
- 18F-FP-DTBZ (18F-AV-133)
- 2h benzo a quinolizin 2 ol 9 3 fluoro sup 18 f propoxy 1 3 4 6 7 11b hexahydro 10 methoxy 3 2 methylpropyl 2r 3r 11br
- 2H-BENZO(A)QUINOLIZIN-2-OL, 9-(3-(FLUORO-(SUP 18)F)PROPOXY)-1,3,4,6,7,11B-HEXAHYDRO-10- METHOXY-3-(2-METHYLPROPYL)-, (2R,3R,11BR)-
- 2r 3r 11br 9 3 sup 18 f fluoropropoxy 10 methoxy 3 2 methylpropyl 1 3 4 6 7 11b hexahydro 2h benzo a quinolizin 2 ol
- av 133 f 18
- AV-133 F-18
- dtbz f 18
- Dtbz f-18
- Florbenazina (18f)
- florbenazina 18f
- Florbenazine (18f)
- florbenazine (¹⁸F) [INN]
- Florbenazine (18f) [WHO-DD]
- florbenazine 18f
And 8 more, listed on the interactive page.
- CAS registry numbers
- 956903-29-0
- ChEMBL ID
- CHEMBL1780010
- InChIKey
- GNKGXQHHUUEYQV-WTHAECTESA-N
- PubChem compound IDs
- 17755050
- FDA ingredient codes (UNII)
- KM31LBX59H
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
Trial references
- NCT02236754
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 41.93
- Calculated partition coefficient (ALogP)
- 3.76
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 26
- Molecular formula
- C21H32FNO3
- Monoisotopic mass
- 364.239156
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 0
Related records
Trials (192)
- 18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging
- 18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism
- 2013/2017 H7N9 Prime-Boost Interval
- 2017 A/H7N9 IIV Revaccination
- A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
- A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition
- A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
- A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
- A Phase 1 Study of XH-S003 in Healthy Volunteers
- A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.
- A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
- A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
- A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
- A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
- A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery
- A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers
- A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
- A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State
In development for (1)
- Type 1 diabetes mellitus Early phase 1